Allon and TURNS expand collaboration for Phase II schizophrenia trial
Dr. Jeffrey Lieberman, Director of the Scientific Operations Unit, Treatment Units for Research on Neurocognition and Schizophrenia, stated that the imaging-biomarker endpoint is important in our understanding of the scope of AL-108 in the treatment of schizophrenia.
"We believe the addition of the imaging-biomarker component to this study will increase our understanding of how this novel compound (AL-108) can improve a patient's cognitive performance through structural changes in the brain." Dr. Lieberman said. "Our hypothesis is that since Allon's AL-108 product is neuroprotective, targeting the microtubules and preserving the structure and function of neurons, changes in specific regions of the brain should be detectable and related to treatment response."
The TURNS-Allon study has received IRB (Institutional Review Board) approval to begin patient enrolment for the Phase II efficacy trial in schizophrenia-related cognitive impairment. The phase II trial is a multicenter, double blind, placebo-controlled study, evaluating AL-108 in chronic schizophrenia. Allon and TURNS expect to begin dosing shortly.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.